Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.

Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue.

In industrial engineering, digital twins—computer models of systems or processes—let scientists try out ideas before finalizing designs. In addition, on the factory floor, twins can model processes in ...

From designing proteins not found in nature to extending healthy lifespan, Retro Biosciences is applying AI models to advance cellular reprogramming for aging research. The company operates across ...

diSArm clinical trial is that our phages injected intravenously can home in to the site of infection, penetrate biofilms, infect, and lyse S. aureus. Many deaths post flu, and most likely also ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity.

Improvements in sensitivity, specificity, and accurate quantitation allow researchers to glean valuable information from hundreds of samples in record time.

Virtual screening methods fall broadly into two categories: ligand- and structure-based. Ligand-based virtual screening doesn’t require a target protein structure, Instead, it leverages known active ...

A new scalable technique enables the generation of human kidney organoids by integrating them into perfused pig kidneys.

Nanoparticles carrying IL-12 are non-toxic, elicit strong systemic antitumor immunity, and sensitize ovarian tumors to ICI therapy, a new study shows.

Virtual cell model development will be driven through tools, data, and benchmarks delivered through CZI’s virtual cells platform (VCP).